Literature DB >> 19961341

Success and spontaneous pregnancy rates following systemic methotrexate versus laparoscopic surgery for tubal pregnancies: a randomized trial.

Lars Bo Krag Moeller1, Charlotte Moeller, Sten Grove Thomsen, Lars Franch Andersen, Lene Lundvall, Øejvind Lidegaard, Jens Joergen Kjer, Jens Lindgren Ingemanssen, Vibeke Zobbe, Charlotte Floridon, Janne Petersen, Bent Ottesen.   

Abstract

OBJECTIVE: To determine which treatment should be offered to women with a non-ruptured tubal pregnancy: a single dose of methotrexate (MTX) or laparoscopic surgery.
DESIGN: Prospective, randomized, open multicenter study.
SETTING: Seven Danish departments of obstetrics and gynecology. SAMPLE: A total of 106 women diagnosed with ectopic pregnancy (EP).
METHODS: Between March 1997 and September 2000, 1,265 women were diagnosed with EP, 395 (31%) were eligible, 109 (9%) were randomized of whom 106 had an EP. The study was originally powered to a sample size of 422 patients. The women were randomized to either medical (MTX; 53) or surgical (laparoscopic salpingotomy; 53) treatment. Follow-up by questionnaire and through national patient databases for a maximum of 10 years. MAIN OUTCOME MEASURES: Uneventful decline of plasma-human chorionic gonadotropin to less than 5 IU/L, rates of spontaneous, subsequent intrauterine, and recurrent ectopic pregnancies.
RESULTS: The success rates were 74% following MTX treatment and 87% after surgery (n.s.); the subsequent spontaneous intrauterine pregnancy rate was 73% after MTX and 62% after surgery; and the EP rate was 9.6% after MTX and 17.3% following surgery (n.s.).
CONCLUSIONS: In women with an EP, who are hemodynamically stable and wishing to preserve their fertility, medical treatment with single dose MTX tends to be equal to treatment with laparoscopic surgery regarding success rate, complications, and subsequent fertility. Although the two treatment modalities seemed to be similar in outcome, it is crucial that the diagnosis is based on a high-quality ultrasonographic evaluation, as two patients had intrauterine pregnancies despite fulfilling the diagnostic algorithm for EP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961341     DOI: 10.3109/00016340903188912

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  9 in total

Review 1.  Tubal ectopic pregnancy.

Authors:  Rajesh Varma; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2012-02-10

2.  Tubal ectopic pregnancy.

Authors:  Vinod Kumar; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2015-11-16

3.  The impact of expectant management, systemic methotrexate and surgery on subsequent pregnancy outcomes in tubal ectopic pregnancy.

Authors:  E Demirdag; I Guler; S Abay; Y Oguz; M Erdem; A Erdem
Journal:  Ir J Med Sci       Date:  2016-02-19       Impact factor: 1.568

4.  Fertility outcome analysis after surgical management of tubal ectopic pregnancy: a retrospective cohort study.

Authors:  Jingwei Li; Kailei Jiang; Fujie Zhao
Journal:  BMJ Open       Date:  2015-09-08       Impact factor: 2.692

5.  A Model to Predict Treatment Failure of Single‑Dose Methotrexate in Patients with Tubal Pregnancy.

Authors:  Si Chen; Fangfang Zhu; Yingxuan Zhang; Jing Li; Jie Gao; Gaopi Deng
Journal:  Med Sci Monit       Date:  2020-05-08

6.  FERTILITY OUTCOMES AFTER MEDICAL AND SURGICAL MANAGEMENT OF TUBAL ECTOPIC PREGNANCY.

Authors:  Senem Arda Düz
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.780

7.  Factors Associated with Ruptured Ectopic Pregnancy: A 10-Year Review at a District Hospital in Ghana.

Authors:  Promise E Sefogah; Nana E Oduro; Alim Swarray-Deen; Hanson G Nuamah; Raphael B Takyi; Mercy A Nuamah; Samuel A Oppong
Journal:  Obstet Gynecol Int       Date:  2022-03-07

8.  Use of FloSeal Sealant in the Surgical Management of Tubal Ectopic Pregnancy.

Authors:  Mara Clapp; Jaou-Chen Huang
Journal:  Case Rep Obstet Gynecol       Date:  2013-05-29

9.  A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol.

Authors:  James May; Colin Duncan; Ben Mol; Siladitya Bhattacharya; Jane Daniels; Lee Middleton; Catherine Hewitt; Arri Coomarasamy; Davor Jurkovic; Tom Bourne; Cecilia Bottomley; Alexandra Peace-Gadsby; Ann Doust; Stephen Tong; Andrew W Horne
Journal:  Trials       Date:  2018-11-20       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.